From Renal and Urology News
Metastasis-directed therapy alone may delay initiation of systemic therapy in select men with a solitary metastasis after hormone-sensitive prostate cancer recurrence, a new retrospective study suggests.
Among 124 patients with solitary oligorecurrent metastases observed on C-11 choline positron emission tomography (PET), 67 received surgical excision and 57 received stereotactic body radiation therapy (SBRT) as metastasis-directed therapy (MDT), without concurrent androgen deprivation therapy (ADT) or systemic therapy. Surgery was mostly recommended for lymph node metastasis. Radiation therapy was mostly recommended for bone metastasis.
PSA decline of more than 50% occurred in 80.5% of the surgery group and 40.3% of the SBRT group, Jack R. Andrews, MD, of Mayo Clinic Arizona in Phoenix and colleagues reported in The Journal of Urology. The 3-year radiographic progression-free survival rate was 29% in the surgery group and 16.5% in the SBRT group.
Reference
Andrews JR, Ahmed ME, Sharma V, et al. Metastasis-directed therapy without androgen deprivation therapy in solitary oligorecurrent prostate cancer. J Urol. 208(6):1240-1249. doi:10.1097/JU.0000000000002898